SECUADO Drug Patent Profile

Which patents cover Secuado, and what generic alternatives are available?

Secuado is a drug marketed by Hisamitsu and is included in one NDA. There are six patents protecting this drug.

This drug has thirty-eight patent family members in nine countries.

The generic ingredient in SECUADO is asenapine. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the asenapine profile page.

DrugPatentWatch^® Generic Entry Outlook for Secuado

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 22, 2033. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for SECUADO

International Patents:	38
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	36
Patent Applications:	156
Drug Prices:	Drug price information for SECUADO
What excipients (inactive ingredients) are in SECUADO?	SECUADO excipients list
DailyMed Link:	SECUADO at DailyMed

See drug prices for SECUADO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SECUADO

NDA:

212268

Dosage:

SYSTEM;TRANSDERMAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for SECUADO

Drug Class

Atypical Antipsychotic

US Patents and Regulatory Information for SECUADO

SECUADO is protected by six US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hisamitsu	SECUADO	asenapine	SYSTEM;TRANSDERMAL	212268-001	Oct 11, 2019		RX	Yes	Yes			Y
Hisamitsu	SECUADO	asenapine	SYSTEM;TRANSDERMAL	212268-003	Oct 11, 2019		RX	Yes	No			Y
Hisamitsu	SECUADO	asenapine	SYSTEM;TRANSDERMAL	212268-002	Oct 11, 2019		RX	Yes	No			Y

EU/EMA Drug Approvals for SECUADO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
N.V. Organon	Sycrest	asenapine	EMEA/H/C/001177Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.	Authorised	no	no	no	2010-09-01

International Patents for SECUADO

When does loss-of-exclusivity occur for SECUADO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

China

European Patent Office

Japan

Poland

Portugal

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SECUADO around the world.

Country	Patent Number	Title	Estimated Expiration
China	104487071
China	104487072
China	104507472

Supplementary Protection Certificates for SECUADO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0746317	C300461	Netherlands		PRODUCT NAME: ASENAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MALEAAT; REGISTRATION NO/DATE: EU/1/10/640/001-006 20100901
0746317	10C0056	France		PRODUCT NAME: ASENAPINE; REGISTRATION NO/DATE: EU/1/10/640/001 20100901
0746317	SPC/GB10/046	United Kingdom		PRODUCT NAME: ASENAPINE; REGISTERED: UK EU/1/10/640/001 20100901; UK EU/1/10/640/002 20100901; UK EU/1/10/640/003 20100901; UK EU/1/10/640/004 20100901; UK EU/1/10/640/005 20100901; UK EU/1/10/640/006 20100901

Last updated: July 29, 2026

SECUADO (asenapine) Market Dynamics and Financial Trajectory: Sales Drivers, Exclusivity, Competition, and Revenue Outlook (US and Key Markets)

Executive summary: SECUADO (asenapine) is positioned as an orally administered second-generation antipsychotic (SGA) delivered via an oral film formulation. Its commercial trajectory is shaped by: (1) US exclusivity and patent-driven generic/biosimilar risk (Orange Book barriers for the specific SECUADO formulation), (2) formulary access relative to competing asenapine products and other SGAs used for schizophrenia and related bipolar indications, (3) payer step-therapy dynamics in commercial and Medicaid formularies, and (4) utilization trends for schizophrenia pharmacotherapy, including how clinicians select among SGAs for tolerability and dosing convenience.

Market outcome depends on whether SECUADO can win share against:

• other asenapine options (notably sublingual asenapine products where available),
• long-acting injectable SGAs (which often win chronic schizophrenia management share with adherence benefits),
• oral SGAs with favorable WAC-to-formulary value propositions.

---

What is SECUADO (asenapine) and what is its commercial use case?

SECUADO is an asenapine product in the antipsychotic class. In the US, asenapine is used for schizophrenia in adults and for bipolar-related indications depending on label specifics. The key commercial driver is the clinical niche of SGAs in schizophrenia and bipolar disorder where prescribers choose based on:

• efficacy consistency across SGAs,
• tolerability (metabolic effects, sedation, akathisia, EPS risk),
• patient preference (oral vs injectable, dosing frequency),
• insurance coverage and prior authorization.

Why the oral film matters for market access

Oral film delivery can be positioned for:

• dosing convenience versus sublingual tablet forms,
• potential adherence improvements versus more complex regimens,
• patient-level usability (film administration can reduce aversion relative to pills for some patients).

For payer dynamics, delivery form matters because it determines whether payers treat the product as substitutable at the pharmacy counter or require PA for brand-only pathways.

---

How do exclusivity and patent terms shape SECUADO’s financial trajectory?

Featured snippet: SECUADO’s revenue runway is determined by the expiration of Orange Book-listed patents and any pediatric exclusivity extensions for the approved formulation. Generic entry timing then depends on paragraph IV filing and litigation outcomes.

What typically drives the SECUADO exclusivity clock

For an NDA product, commercial defensibility in the US depends on:

1. patent term end dates for listed composition, formulation, and method-of-use claims,
2. pediatric exclusivity (if applicable) extending regulatory exclusivity rather than primary patent term,
3. regulatory exclusivity categories tied to the approval pathway (NCE/BLA/505(b)(2) and whether exclusivity was granted).

Generic entry risks for SECUADO

The critical business question for revenue forecasting is not “Will generics exist?” but:

• when generic manufacturers can launch without willful infringement,
• whether SECUADO patents require design-arounds (formulation and process constraints),
• whether at-launch supply and contracting speed can drive rapid WAC discounting.

Market impact mechanics:

• After first generic launch, brand pricing usually compresses through contracting. Loss of commercial share often outpaces share loss in early Medicaid where brand retention can persist under higher copay or medical-necessity policy.
• If SECUADO is classified on formulary tiers as preferred, net price retention improves.

---

What patents protect SECUADO and how many are in the estate?

Featured snippet: The patent estate strength for SECUADO is measured by the number of Orange Book-listed patents (and their remaining term) tied to the approved NDA and each dosage form.

Patent-ecosystem drivers that move revenue

For SGAs, revenue is usually protected by combinations of:

• composition-of-matter patents on asenapine derivatives or salts (where applicable),
• formulation patents specific to film technology,
• method-of-use patents aligned with label indications.

Financial consequence:

• Film-specific formulation patents can deter “drop-in” generics even when active ingredient patents are expired.
• Method-of-use patents can delay section viii carve-outs only if generic labeling is constrained through statutory labeling carve-out.

Litigation as a forecast variable

In US branded launches, Paragraph IV challenges can create:

• early generic entry under settlements,
• extended brand monopoly through anti-infringement wins,
• partial carve-outs that fragment indication coverage.

For SECUADO, revenue sensitivity is highest around:

• first generic filing date (a proxy for market readiness),
• first court decisions on key claims,
• any settlement terms that set “design launch” timing.

---

What is the Orange Book status of SECUADO?

Featured snippet: Orange Book status determines whether generic approval is blocked by patent listed for the specific drug product and whether a Paragraph IV notice is tied to those patents.

What an Orange Book “protected drug” usually implies commercially

If SECUADO lists multiple patents covering formulation and/or method-of-use, then:

• an ANDA applicant filing with Paragraph IV typically faces higher infringement risk,
• brand can maintain formulary position longer if payer policies depend on “no generic equivalents.”

Commercial impact is more visible when:

• payers enforce interchangeability rules,
• pharmacy benefit managers push to lowest-cost alternatives.

---

When does SECUADO lose exclusivity and what are the likely launch scenarios?

Featured snippet: Loss of exclusivity drives the highest risk of net price compression and share erosion. Launch scenarios hinge on whether generic entry is early, settled, or fully litigated.

Three high-probability generic scenarios

1. Litigation win for brand: delayed generic entry, price compression limited to therapeutic class competition.
2. Paragraph IV settlement: earlier than full term but later than immediate patent invalidation; brand retains partial share while generic ramps.
3. Litigation loss or invalidation: faster launch, larger share shift, steeper net-to-gross compression.

Revenue outcome sensitivity

A schizophrenia SGA’s branded revenue can hold up if:

• generic entry is delayed beyond peak market maturity,
• SECUADO retains preferred formulary position due to patient-specific criteria,
• payers do not view other asenapine products as equivalent for step-therapy.

---

How does SECUADO compare with other asenapine and schizophrenia drugs on the US market?

Featured snippet: SECUADO competes within the SGA class and also against asenapine alternatives. The differentiator is administration convenience and formulary standing.

Competitive comparison matrix (decision-useful)

Competitor set	Typical payer/clinician dynamics	Key threat to SECUADO revenue
Other asenapine formulations (non-SECUADO)	Treated as same active ingredient with varying coverage rules	Tier placement and copay policies
Oral SGAs (e.g., olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone)	High switching sensitivity after generic availability	Net price compression across class
Long-acting injectables (LAIs)	Strong adherence and continuity benefits	Share shift for chronic schizophrenia
Clozapine (treatment-resistant schizophrenia)	Used after inadequate response	No direct near-term replacement unless label expands

What usually determines market share in schizophrenia

• prior authorization requirements,
• step therapy for first episode vs chronic patients,
• clinician familiarity and patient adherence patterns,
• pharmacoeconomic evaluations and gross-to-net trends.

---

What payer and formulary dynamics drive SECUADO demand?

Featured snippet: SECUADO demand is shaped by formulary tiering, copay assistance, PA triggers, and switching protocols within SGA management.

Commercial and Medicaid coverage mechanics

• Commercial plans: prefer preferred brand or lowest-cost generic substitutes once available. Brand can offset through rebates and patient assistance, but those increase gross-to-net discount pressure.
• Medicaid: often has less flexibility; state formularies can be either brand-favorable or brand-restrictive depending on administrative criteria and budget pressures.

Step-therapy and prior authorization

For antipsychotics, insurers commonly require:

• documented prior SGA trials for certain subgroups,
• stability criteria for continuation therapy,
• adherence or side effect justification.

SECUADO’s oral film may help on PA if prescribers document inability to swallow or adherence issues.

---

How many brands/generics exist for comparable asenapine use, and what does that imply?

Featured snippet: If multiple asenapine alternatives exist on formulary, SECUADO faces active substitution pressures. If its film formulation is treated as non-interchangeable, it can retain more shelf stability until product-level generics enter.

Substitution risk by active ingredient vs product

• Active ingredient substitution risk increases when generics for asenapine are available and are preferred by PBMs.
• Product substitution risk increases when payers treat SECUADO as clinically substitutable and interchangeably priced.

Net effect: SECUADO’s financial trajectory typically depends more on the product-level generic threat than on class-level competition alone.

---

What role do rebates and net price compression play in SECUADO’s financial trajectory?

Featured snippet: Gross revenue can remain stable while net revenue falls as rebates rise to defend share against therapeutic and product substitutes.

Gross-to-net under competition

As generic entry approaches or as competing SGAs gain preferred status:

• rebate rates often increase,
• contracting shifts toward outcomes and utilization guarantees,
• access becomes narrower by plan type.

Forecast implication: even without immediate generic entry, SECUADO’s profitability can compress via rebate escalation.

---

What manufacturing and IP barriers could affect SECUADO’s ability to maintain supply and defend share?

Featured snippet: SECUADO’s risk profile includes supply continuity, film manufacturing scale-up constraints, and process-related patent or trade secret boundaries that can affect generic design-around ability.

Supply chain considerations

• film manufacturing requires consistent dosage uniformity and stability,
• regulatory inspections and lot release timelines can drive intermittent supply issues,
• shortages can shift patients to other SGAs and may not fully revert post-resolution.

IP and “design-around”

Film-specific process claims can make generic development slower:

• formulation and manufacturing process differences can be expensive and time-consuming to validate,
• if patents cover critical process parameters, generic applicants may need more extensive development to reduce infringement risk.

---

What patent litigation affects SECUADO and how do settlements change launch timing?

Featured snippet: Patent litigation outcomes set the launch timetable and can create “soft barriers” via delayed launch in settlement agreements.

Litigation pathways that matter

• Paragraph IV ANDA notices (if filed for generic/asenapine film equivalents),
• motions for preliminary injunctions in rare high-stakes cases,
• infringement/non-infringement decisions by district courts,
• Federal Circuit appeals that can extend resolution timelines.

Settlement terms that drive commercial outcomes

Common settlement mechanisms include:

• agreed launch dates,
• exclusivity for authorized generics,
• permissible launch at only non-infringing dosage forms or strengths (where applicable).

---

How will SECUADO’s revenue likely evolve under three generic launch scenarios?

Featured snippet: Brand revenue typically declines sharply after first product-level generic launch unless SECUADO remains preferred and rebates offset net price declines.

Scenario table (planning-grade)

Scenario	Timing driver	Brand impact	PBM/payer response	Strategic implication
Delay via litigation	Patent survives or injunction holds	Slower share loss	Maintain brand preferencing longer	Invest in evidence generation and formulary marketing
Settlement with mid-term launch	Court or settlement sets fixed date	Gradual erosion, net price pressure	Increased switching only after settlement launch window	Prepare contracting and co-pay strategy
Fast generic entry	Invalidation or settlement with near-term date	Steeper share shift	Rapid substitution and tier downgrades	Pivot to indication expansion or differentiation

---

Key Takeaways

• SECUADO’s financial trajectory is driven by product-level exclusivity tied to its oral film formulation and any Orange Book-listed patents covering composition, formulation, and method-of-use claims.
• The biggest revenue inflection typically comes from generic launch timing for film-equivalent products and any Paragraph IV challenges that alter exclusivity end dates.
• Commercial demand depends on formulary tiering, PA criteria, and rebate pressure as the SGA competitive set broadens.
• Long-acting injectables and other oral SGAs influence market share even before generic asenapine film threats fully materialize.
• Supply continuity and contracting strategy can determine how much revenue is “lost” through utilization switching versus net price erosion.

---

FAQs

1. How does SECUADO compare on formulary placement versus other asenapine products?
2. What is the revenue impact of a generic launch for an asenapine film versus a generic for another SGA?
3. Does SECUADO face greater substitution risk from active-ingredient generics or from film-specific product generics?
4. How do PA and step-therapy rules typically influence branded antipsychotic persistence?
5. What contract levers (rebates, copay support, outcomes contracts) most affect gross-to-net for SECUADO?

---

References (APA)

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (n.d.). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA Drug Labels (SECUADO). (n.d.). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
3. Federal Trade Commission. (n.d.). Generic competition and brand drug pricing dynamics. https://www.ftc.gov/